Literature DB >> 6824467

Electroretinography in the prognosis and classification of central retinal vein occlusion.

R Sabates, T Hirose, J W McMeel.   

Abstract

Forty-five patients with a central retinal vein occlusion were divided into three groups: those with venous stasis retinopathy (VSR, n = 27), those with hemorrhagic retinopathy (HR, n = 6), and those with undetermined retinopathy (n = 12). The electroretinogram (ERG) was recorded in all cases. The average b/a-wave amplitude ratio of the single white-flash ERG was 1.67 for the VSR group and 0.70 for the HR group. The ERG responses in the group with undetermined retinopathy helped to assess the degree of retinal ischemia and to further categorize the disorder as either VSR or HR. The b/a amplitude ratio reflected the degree of retinal ischemia and had prognostic value in predicting in which cases neovascular glaucoma may develop. The average b/a ratio in the six cases in which neovascular glaucoma developed was 0.84. This complication did not develop in any patient with a b/a ratio greater than 1. Four patients with low b/a ratios (average, 0.73) were treated with panretinal photocoagulation; neovascular glaucoma developed in none.

Entities:  

Mesh:

Year:  1983        PMID: 6824467     DOI: 10.1001/archopht.1983.01040010234010

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  27 in total

1.  The a- and b-wave latencies as a prognostic indicator of neovascularisation in central retinal vein occlusion.

Authors:  M Moschos; D Brouzas; M Moschou; G Theodossiadis
Journal:  Doc Ophthalmol       Date:  1999       Impact factor: 2.379

2.  Extraction and modeling of the Oscillatory Potential: signal conditioning to obtain minimally corrupted Oscillatory Potentials.

Authors:  Peter H Derr; Andrew U Meyer; Edward J Haupt; Mitchell G Brigell
Journal:  Doc Ophthalmol       Date:  2002-01       Impact factor: 2.379

3.  Wide field multifocal and standard full field electroretinographic features of hemi retinal vein occlusion.

Authors:  Fiona Mary Dolan; Stuart Parks; David Keating; Gordon Neale Dutton
Journal:  Doc Ophthalmol       Date:  2006-01       Impact factor: 2.379

4.  Systemic human CR2-targeted complement alternative pathway inhibitor ameliorates mouse laser-induced choroidal neovascularization.

Authors:  Bärbel Rohrer; Beth Coughlin; Mausumi Bandyopadhyay; V Michael Holers
Journal:  J Ocul Pharmacol Ther       Date:  2012-02-06       Impact factor: 2.671

5.  The Royal College of Ophthalmologists Guidelines on retinal vein occlusions: executive summary.

Authors:  S Sivaprasad; W M Amoaku; P Hykin
Journal:  Eye (Lond)       Date:  2015-08-28       Impact factor: 3.775

6.  Changes of electroretinogram without improvement of retinal circulation after radial optic neurotomy for central retinal vein occlusion. ERG changes after RON for CRVO.

Authors:  Eiju Sato; Shuichi Yamamoto; Kazuha Ogata; Mariko Kubota; Takeshi Sugawara; Satoshi Mizunoya
Journal:  Doc Ophthalmol       Date:  2008-01-01       Impact factor: 2.379

7.  The flicker electroretinogram interocular amplitude ratio is a strong prognostic indicator of neovascularization in patients with central retinal vein occlusion.

Authors:  Hsi-Kung Kuo; Ming-Tse Kuo; Yung-Jen Chen; Pei-Chang Wu; Chih-Hsin Chen; Yi-Hao Chen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-10-08       Impact factor: 3.117

Review 8.  Central retinal vein occlusion: what's the story?

Authors:  T H Williamson
Journal:  Br J Ophthalmol       Date:  1997-08       Impact factor: 4.638

9.  Comparison of electroretinographic measurements between tabletop and handheld stimulators in healthy subjects.

Authors:  Bum G Kim; In B Chang; Kyeong D Jeong; Jae Y Park; Jae S Kim; Je Hyung Hwang
Journal:  Doc Ophthalmol       Date:  2019-03-18       Impact factor: 2.379

10.  Differentiation of ischemic from non-ischemic central retinal vein occlusion during the early acute phase.

Authors:  S S Hayreh; M R Klugman; M Beri; A E Kimura; P Podhajsky
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1990       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.